About US
Contact us
-
Teva scrambling toward post-Copaxone futureTeva Pharmaceutical Industries ($TEVA)has been the world's biggest generics player for years. Problem is, it's trying to be more than that. And makeovers take time. Midway throughlast year, analysts w2012/2/16
-
A bright side to Europe's woes: U.S., Japan look betterEurope is making the U.S. and Asia look much sweeter to drugmakers. Price cuts, slow adoption of new medicines, and, of course, unpaid bills, have disillusioned pharma companies accustomed to counting2012/2/16
-
Old drug + potential new use = headache for pharmaPotential new uses for approved drugs crop up regularly. Most drug companies build their business plans around adding indications to new products; after all, the more patients who are eligible to us2012/2/15
-
GSK's office-space overhaul part of bigger changesGlaxoSmithKline ($GSK) employees in the Philadelphia area face big changes in the way they work as the company prepares to relocate to a new building in the Navy Yard. But those changes are only part2012/2/15
-
Lonza teams with S. Africa on antiretroviral API plantSwiss drug manufacturer Lonza has allied with the South African government on a new, $210 million plant to produce antiretroviral APIs. The venture, dubbed Ketlaphela, is aimed at reducing drugmaker2012/2/14
-
Gene study finds tumor-cell flaw possibly vulnerable to Pfizer, AZ cancer medsMore evidence that drugs and diagnostics will be playing together often: Researchers sequencing genes in colon and lung tumors found mutations that could be targeted with existing drugs. The study e2012/2/14
-
GSK, Takeda say nay to in-house diagnostics unitsGlaxoSmithKline ($GSK) and Takeda Pharmaceutical are choosing the partnerships side of the divide when it comes to developing diagnostics to team up with their drugs. Both companies have said they2012/2/13
-
Merck says Victrelis can interfere with HIV medsMerck ($MRK)has notified doctors that its new hepatitis C drug Victrelis interferes with commonly used AIDS drugs. Victrelis can reduce the effectiveness of the HIV-fighters--and vice-versa--Merck s2012/2/13
-
Novartis CEO calls external focus key to fast-changing pharmaThe idea of facing generic competition for a $5 billion blockbuster like Diovan would daunt almost any CEO. But Joe Jimenez (photo) says his experience hawking baby food and ketchup at Heinz m2012/2/10
-
Judge: No 1st Amendment shield for Astellas' Prograf petitionJapan's Astellas Pharma has to fight antitrust claims related to its transplant drug Prograf. The drugmaker failed to persuade a U.S. judge to dismiss consumer allegations it petitioned the FDA2012/2/10